THEMATIC REVIEW

40 YEARS OF IGF1

Role of IGF1 and EFN–EPH signaling in skeletal metabolism

Richard C Lindsey^{1,2,3,*}, Charles H Rundle^{1,4,*} and Subburaman Mohan^{1,2,3,4}¹Musculoskeletal Disease Center, VA Loma Linda Healthcare System, Loma Linda, California, USA²Division of Biochemistry, Department of Basic Sciences, School of Medicine, Loma Linda University, Loma Linda, California, USA³Center for Health Disparities and Molecular Medicine, Department of Basic Sciences, School of Medicine, Loma Linda University, Loma Linda, California, USA⁴Department of Medicine, Loma Linda University, Loma Linda, California, USACorrespondence should be addressed to S Mohan: subburaman.mohan@va.gov

*(R C Lindsey and C H Rundle contributed equally to this work)

This paper forms part of a special section on 40 years of IGF1. The guest editors for this section were Derek LeRoith and Emily Gallagher.

Abstract

Insulin-like growth factor 1 (IGF1) and ephrin ligand (EFN)–receptor (EPH) signaling are both crucial for bone cell function and skeletal development and maintenance. IGF1 signaling is the major mediator of growth hormone-induced bone growth, but a host of different signals and factors regulate IGF1 signaling at the systemic and local levels. Disruption of the *Igf1* gene results in reduced peak bone mass in both experimental animal models and humans. Additionally, EFN–EPH signaling is a complex system which, particularly through cell–cell interactions, contributes to the development and differentiation of many bone cell types. Recent evidence has demonstrated several ways in which the IGF1 and EFN–EPH signaling pathways interact with and depend upon each other to regulate bone cell function. While much remains to be elucidated, the interaction between these two signaling pathways opens a vast array of new opportunities for investigation into the mechanisms of and potential therapies for skeletal conditions such as osteoporosis and fracture repair.

Key Words

- ▶ IGF1
- ▶ EFN
- ▶ EPH
- ▶ bone

*Journal of Molecular
Endocrinology*
(2018) **61**, T87–T102

Introduction

Osteoporosis is a debilitating disease affecting millions worldwide. In the United States alone, more than 10 million people have osteoporosis, and that number is predicted to rise, increasing the burden of suffering as well as healthcare costs on individuals as well as society at large. By the year 2025, the annual rate of osteoporosis-related fractures in the United States has been projected to be greater than 3 million, leading to an economic burden of more than \$25 billion per year (Burge *et al.* 2007). Osteoporosis, a

disease characterized by low bone mass and compromised skeletal microarchitecture, occurs when elevated rates of bone resorption are not sufficiently compensated for by increased bone formation. Frequently, osteoporosis occurs in the context of accelerated bone resorption due to sex hormone deficiency and aging in postmenopausal women. While several current therapeutic strategies have achieved some success at slowing the rate of bone loss, devastating osteoporotic fractures still occur at an alarming

rate, emphasizing both the importance of achieving a high peak bone mass during development and the necessity of investigating the mechanisms regulating bone growth and maintenance in order to develop new therapies to treat and prevent osteoporosis. Much work has gone into understanding of the origin and functions of cartilage-forming chondrocytes, bone matrix-producing osteoblasts and osteocytes and bone-resorbing osteoclasts, and these studies have revealed that the network of signals regulating these cells and their functions is complex. Indeed, there are many growth factors that contribute to the regulation of skeletal development. Two growth factor signaling pathways that exert many effects on skeletal development are the IGF1 and EFN–EPH pathways. The focus of this review is to explore the extent to which each of these two signaling pathways has been studied with respect to its contribution to skeletal development and to review what is currently known about the ways in which the interactions of these two pathways may enhance our understanding of skeletal regulation and lead to opportunities to discover novel therapies for osteoporosis and bone repair.

IGF signaling in bone

IGFs are the most abundant growth factors in bone matrix and are critical regulators of bone growth and maintenance. IGF-1 and -2 are small peptide hormones that are structurally similar to insulin, and they act by binding the type I IGF receptor (IGF1R), a receptor tyrosine kinase, which is also structurally similar to the insulin receptor (Centrella

et al. 1990, Slootweg *et al.* 1990). During intrauterine development, IGF2 is responsible for growth, while IGF1 predominantly regulates skeletal growth and maintenance during postnatal life. As a member of the growth hormone (GH)/IGF axis, IGF1 is responsible for mediating a significant proportion of GH's effects on bone (Fig. 1).

GH regulation of IGF1

The systemic, endocrine actions of IGF1 are largely due to GH-induced hepatic IGF1 secretion into the circulation. In fact, conditional hepatic deletion of the *Igf1* gene (Sjögren *et al.* 1999, Yakar *et al.* 1999) or GH receptor (*Ghr*) gene (Fan *et al.* 2009) in mice resulted in up to 90% reductions in systemic circulating IGF1 levels. Furthermore, up to 75% of circulating IGF1 is bound up in a ternary complex with IGF-binding protein 3 (IGFBP3) and an acid-labile subunit (ALS), which is also produced in the liver in response to GH signaling. Growth hormone-induced hepatic secretion of circulating, endocrine-acting IGF1 may be responsible for up to 30% of body weight (Stratikopoulos *et al.* 2008). However, IGF1 also acts locally in an autocrine/paracrine manner. An additional 39% of body weight may be due to local IGF1 production, of which 4% may be accounted for by GH-induced IGF1 production in peripheral tissues (Stratikopoulos *et al.* 2008).

As IGF1 is known to interact with EFN–EPH signaling and IGF1 mediates many of GH's effects on bone, this review focuses primarily on the contribution of IGF signaling to skeletal development. However, the entire

Figure 1

A model of GH/IGF1 and sex hormone signaling interacting to regulate bone growth. GH effects on the skeletal system are mediated via both endocrine and local mechanisms through hepatic IGF1 and local modulation of IGF1 expression in bone cells, respectively. Sex steroids contribute relatively little to longitudinal bone growth, but they interact with IGF1 signaling to regulate radial bone growth. The interaction of IGF1 and sex steroid signaling results in skeletal sexual dimorphism in which, during pubertal growth, male (M) periosteal bone formation (BF) and endosteal bone resorption (BR) are both increased, producing bones with a larger diameter as well as a larger marrow cavity, while female (F) periosteal BF is increased but endosteal BR is decreased, leading to smaller bones with more preservation of cortical bone (Adapted with permission from Lindsey & Mohan 2016).

GH/IGF axis is crucial for skeletal development, and other recent reviews have examined the GH/IGF axis as a whole (Locatelli & Bianchi 2014, Lindsey & Mohan 2015, Liu *et al.* 2016). Furthermore, some evidence suggests that the GHR and downstream effectors of GH signaling Janus kinase 2 (JAK2) and signal transducer and activator of transcription 5B (STAT5B) may complex with EPHA4 to enhance *Igf1* expression, suggesting a more complex relationship between the GH/IGF axis and EFN–EPH signaling, which deserves further investigation (Jing *et al.* 2012; see below).

Systemic regulation and effects of IGF1

Many systemic signals in addition to GH are known to regulate IGF1. For example, circulating parathyroid hormone (PTH) is known to enhance osteoblast proliferation, differentiation and survival by increasing local production of IGF1 (Linkhart & Mohan 1989, McCarthy *et al.* 1989, Miyakoshi *et al.* 2001a, Bikle *et al.* 2002, Yamaguchi *et al.* 2005). Additionally, sex steroids cause an increase in IGF1 expression during puberty (Christoforidis *et al.* 2005, Veldhuis *et al.* 2005). In fact, crosstalk between the sex steroid and GH/IGF1 axes is crucial for linear bone growth and acquisition, and GH/IGF1 may contribute to the development of skeletal sexual dimorphism (Liu *et al.* 2016). Furthermore, thyroid hormone (TH) increases both hepatic and skeletal IGF1 expression during a critical prepubertal growth period in mice in which TH is a more critical regulator of skeletal growth than GH; thus, IGF1 is thought to mediate many TH effects on the skeleton (Xing *et al.* 2012, Cheng *et al.* 2016). Conversely, glucocorticoids and 1,25-dihydroxyvitamin D3 [1,25-(OH)₂D3] have been shown to downregulate IGF1 expression (Chen *et al.* 1991, Scharla *et al.* 1991, Canalis 2005). Thus, there is ample evidence in the literature to suggest that many of the systemic effects of calcium regulating hormones on bone are mediated in part via regulation of IGF actions.

Local regulation and effects of IGF1

At the local level, many growth factors and other signals in addition to GH are involved in regulating IGF expression. For example, fibroblast growth factor (FGF) 2, transforming growth factor (TGF)-β1, bone morphogenetic protein (BMP) 7 and interleukin-1 are known to influence expression of IGF1 in bone cells (Tremollieres *et al.* 1991, Knutsen *et al.* 1995, McCarthy & Centrella 2001, Zhang *et al.* 2002a). These studies have shown that the actions of many of the local growth

factors on IGF1 expression vary depending on both cell type and stage of differentiation.

IGF activity, however, is dependent upon more than just the regulation of IGF expression levels. IGF1 interacts with several IGF-binding proteins (IGFBP-1 through -6), which serve to regulate IGF1 activity at both the systemic and local levels. Up to 75% of the IGF1 in plasma is bound up in a ternary complex with IGFBP-3 and an ALS, and in this way, IGFBP3 regulates the concentration of active, free IGF1 available in circulation for signaling (Bagi *et al.* 1994, Rosen *et al.* 1994, Jones & Clemmons 1995, Rajaram *et al.* 1997). Not all IGFBPs affect IGF1 signaling in the same way; generally, IGFBP-3 and -5 enhance IGF1's effect on osteoblasts by prolonging its half-life in circulation while IGFBP-1, -2, -4 and -6 inhibit IGF1's effect on osteoblasts by preventing its interaction with the type I IGF receptor (IGFIR) (Govoni *et al.* 2005). Moreover, IGFBPs themselves are regulated at the expression level by systemic and local factors including PTH, 1,25-(OH)₂D3, glucocorticoids, estrogen, retinoic acid, IGFs, TGFβ1, BMPs, PDGF and interleukins (Knutsen *et al.* 1995, Chevalley *et al.* 1996, Gabbitas & Canalis 1996, Honda *et al.* 1996, Hayden *et al.* 1997, Malpe *et al.* 1997, Kveiborg *et al.* 2001, Denger *et al.* 2008, DeMambro *et al.* 2015). IGFBP activity is also regulated by IGFBP proteases including pregnancy-associated plasma protein (PAPP)-A, PAPP-A2 (Kanzaki *et al.* 1994, Conover 1995, Qin *et al.* 2006, Tanner *et al.* 2008, Christians *et al.* 2013), and ADAM-9 (Mohan *et al.* 2002). Regulation of IGF activity by IGFBPs and, by extension, regulation of the IGFBPs themselves are therefore further crucial determinants of IGF signaling in bone.

IGF1 and mechanotransduction

Considerable experimental evidence indicates that mechanical strain is a key physiological regulator of bone formation. IGF1 plays an important role in mechanotransduction and the skeletal response to mechanical strain (Tian *et al.* 2018). Mechanical loading leads to a rapid increase in IGF1 expression in bones (Lean *et al.* 1995, Xing *et al.* 2005, Reijnders *et al.* 2007), an effect which is mediated via an integrin-dependent phosphorylation of the IGF1 receptor (IGFIR) (Kapur *et al.* 2005, Lau *et al.* 2006). *In vivo* overexpression of *Igf1* in mouse osteoblasts led to increased periosteal bone formation in response to low-magnitude loading (Gross *et al.* 2002), and osteoblasts exposed to dynamic strain demonstrate increased activation of PI3K/Akt and β-catenin, downstream effectors of IGF1 signaling (Sunters *et al.* 2010). Furthermore, conditional knockout

of *Igf1* in osteoblasts expressing type I collagen (Col1), Kesavan *et al.* 2011) or osteocytes (Lau *et al.* 2013) prevented an osteogenic response to mechanical loading. In osteocytes, lack of *Igf1* disrupted mechanical strain-induced changes in expression of sclerostin and Wnt10b (Lau *et al.* 2013). In addition to its contributions to the response of osteoblasts and osteocytes to mechanical strain, IGF1 signaling may even play a role in mediating the ability of mechanical forces to regulate the proliferation, survival and osteogenic differentiation of bone marrow-derived mesenchymal stem cells (Sakata *et al.* 2003, 2004, Chen *et al.* 2017, Wang *et al.* 2017). Thus, IGF1 signaling is essential for the skeletal response to mechanical stimuli.

Nutrition and IGF1

Diet and nutritional status are additional important regulators of IGF1 (Bonjour 2016). Under conditions of restricted dietary intake, IGF1 levels are reduced via several mechanisms: hepatic GH receptors are reduced in number, decreasing IGF1 production, and rates of IGF1 degradation and clearance are increased (Thissen *et al.* 2004). Furthermore, osteoblasts appear to be resistant to IGF1 action in the context of protein restriction (Bourrin *et al.* 2000). This IGF1 response to alternations in dietary protein intake specifically has been confirmed in both *in vivo* animal studies (Ammann *et al.* 2000, Bourrin *et al.* 2000) and patients after hip fracture (Schürch *et al.* 1998). The interaction of dietary protein and IGF1 may thus influence skeletal health on a number of levels including attainment of peak bone mass (Bonjour *et al.* 2007), skeletal response to physical activity (Chevalley *et al.* 2008) and bone loss in the context of calorie-poor conditions such as intensive exercise and anorexia nervosa (Russell *et al.* 1994, Grinspoon *et al.* 2000, Gremion *et al.* 2001, Warren *et al.* 2002, Misra *et al.* 2008). Additionally, epidemiological studies indicate that higher protein intake may be protective against bone loss, musculoskeletal deterioration and decreased IGF1 levels, particularly in the elderly (Dawson-Hughes *et al.* 2004, Gaffney-Stomberg *et al.* 2009, Bonjour 2016). Adequate nutrition and protein intake are thus crucial for skeletal development and maintenance.

Transgenic mouse models of IGF1 action

The question of the relative contributions of endocrine vs local IGF1 action to skeletal growth and maintenance has also been extensively studied. Several transgenic mouse models indicate that systemic IGF1 has a much

larger effect on cortical bone size and expansion than on longitudinal bone growth. Mice with conditional disruption of hepatic *Igf1* (Sjögren *et al.* 1999, Yakar *et al.* 1999) or GH receptor (*Ghr*, Fan *et al.* 2009) had little-to-no reduction in linear bone growth despite up to 90% reductions in circulating IGF1 levels. Furthermore, mice with conditional disruption of hepatic IGF1 along with total ALS or total ALS and total IGFBP-3 had up to 97.5% decreases in circulating IGF1 levels; these mice had relatively small changes in body length, but the triple-negative mice had a 50% reduction in cortical bone (Sjögren *et al.* 1999, Yakar *et al.* 1999, 2002, 2009), a similar reduction to that seen in mice lacking total IGF1 (Mohan *et al.* 2003). However, restoration of hepatic IGF1 production in total *Igf1*-knockout mice rescued body size by approximately 30% (Stratikopoulos *et al.* 2008), indicating that endocrine IGF1 action may play a role in skeletal growth (Nordstrom *et al.* 2011, List *et al.* 2014).

Local expression of IGF1 is also critical for bone function. Overexpression of IGF1 in mouse osteoblasts *in vivo* has led to increased osteoblast activity, bone formation and bone remodeling (Zhao *et al.* 2000, Jiang *et al.* 2006), and overexpression of regulators of IGF bioavailability including IGFBPs and their proteases suggests that local availability of IGF1 is an important determinant of bone formation (Miyakoshi *et al.* 1999, Richman *et al.* 1999, Zhao *et al.* 2000, Miyakoshi *et al.* 2001b, Devlin *et al.* 2002, Qin *et al.* 2006). Conditional disruption of *Igf1* and *Igf1r* specifically in osteoblasts confirmed that, while serum levels of IGF1 were unchanged, a lack of local IGF1 significantly impaired bone mineral density (BMD), bone size and bone formation measures (Zhang *et al.* 2002b, Govoni *et al.* 2007a). Furthermore, local IGF1 expression in chondrocytes is also necessary for skeletal development; chondrocyte-specific *Igf1* disruption in mice decreased bone length and BMD and impaired growth plate organization and function (Govoni *et al.* 2007b, Wang *et al.* 2011, 2015). Thus, both systemic and local IGF1 contribute significantly to skeletal growth and maintenance.

IGF1 and osteoporosis

It has been well established that GH secretion decreases with age (Corpas *et al.* 1993, Müller *et al.* 1999). Accordingly, levels of IGF1 in the serum and bone decrease with age as well (Benbassat *et al.* 1997, Seck *et al.* 1999). However, in addition to decreased levels of IGF1 with age, osteoprogenitor cells from aged rats do not respond as effectively to IGF1 (Tanaka & Liang 1996), indicating that the skeleton is particularly susceptible to deterioration

with age. In fact, age is a major risk factor for osteoporosis, and IGF1 may play an important mechanistic role in explaining age-related bone loss.

Epidemiological evidence suggests that IGF1 levels are well correlated with BMD in men and postmenopausal women (Muñoz-Torres *et al.* 2001, Gillberg *et al.* 2002), and a cross-sectional study indicated that elderly women who had sustained femoral neck fractures had significantly decreased levels of IGF1, IGF2, IGFBP3 and IGFBP5 (Boonen *et al.* 1999). Moreover, several recent studies have also observed relationships between deficiencies in components of the IGF system and increased rates of fracture in both women and men (Ohlsson *et al.* 2011, Paccou *et al.* 2012, van Varsseveld *et al.* 2015, Lundin *et al.* 2016). Recombinant human IGF1 has even undergone clinical trials as an osteoporosis treatment, with mainly positive results (Locatelli & Bianchi 2014). However, additional studies have reported little-to-no effect of IGF1 levels on fracture risk (Kassem *et al.* 1994, Seck *et al.* 1999, Gillberg *et al.* 2001, Martini *et al.* 2001, Zofková *et al.* 2001). Thus, while IGF1 may play a role in age-related bone loss and osteoporosis, further studies are needed to elucidate its precise contribution. Taken together, both animal studies and human clinical studies dealing with different aspects of bone formation have established IGF1 as a critical mediator of bone growth and homeostasis.

Ephrin/EPH signaling in bone

The ephrins are large families of membrane-bound ligands (EFN: ephrin family receptor interacting proteins) and receptor tyrosine kinase receptors (EPH: erythropoietin-producing human hepatocellular receptors) that mediate cell–cell communication within and between tissues in a wide variety of biological functions. EFN–EPH mediate cell proliferation and migration, and they are critical in the regulation of adhesion, repulsion and tension, which segregates cells to establish and maintain tissue boundaries during development (Cayuso *et al.* 2015). The EFNs and EPHs are broadly expressed during tissue development and repair. These functions have also implicated the EFNs and EPHs in the dysregulated adhesion and motility that promotes tumor metastasis.

There are two families of ephrin ligands. In mammals, they comprise the five-member ephrin A (EFNA) family of glycosylphosphatidylinositol (GPI)-linked ligands and the three-member ephrin B (EFNB) family of transmembrane ligands. EFN-binding receptors are all receptor tyrosine kinase (RTK) receptors, but they belong to either the nine-member A receptor (EPHA) family or the

five-member B receptor (EPHB) family. Both EPHA and EPHB have an extracellular EFN-binding domain attached to two fibronectin-III repeats and the intracellular tyrosine kinase, sterile alpha motif (SAM) and postsynaptic density protein 95/disk large/zonula occludens-1 (PDZ)-binding domains. Ligand–receptor interactions can be promiscuous within the ligand–receptor family, but, with few exceptions, signaling is restricted between ligands and receptors within either the A or B family.

Forward and reverse signaling

EFNB and EPHB regulation of tissue development and homeostasis is noteworthy because this family can signal in the forward direction, from ligand through receptor, as well as in the reverse direction, from receptor through ligand, through a PDZ-binding motif connected to the intracellular cytoplasmic domain. Reverse signaling from EPHA through EFNA is not well characterized, but this pathway might utilize regulatory proteins recruited to EFNA clusters (Davy *et al.* 1999).

EPH receptor and binding diversity permits a wide array of forward and reverse signaling options to mediate their functions. EPHA regulates the JAK/STAT pathway, while EPHB regulates PI3 kinase-mediated proliferation. Activation of the Rho GTPases by EPHA or EPHB mediates actin effects on cell shape and movement. Activation of the Ras GTPase pathways generally leads to negative regulation of the MAP kinase pathway, resulting in reduced proliferation and migration by EPHA as well as reduced adhesion by EPHB (Edwards & Mundy 2008). Reverse signaling from EPHB2 through EFNB1 promotes stromal cell differentiation to osteoblasts. In this case, PDZ domains from EFNB1 and the PDZ-containing protein Na/H exchange regulatory factor 1 (NHERF1) form a complex with protein tyrosine phosphatase (PTPN13) and the PDZ domain-binding transcriptional coactivator (TAZ) to promote *Osx* transcription and osteoblast differentiation (Xing *et al.* 2010). Other studies have demonstrated the interaction of EFNs with various adaptor proteins, further increasing the potential of EFN–EPH signaling to interact with diverse signaling partners. For example, the SH2/SH3 adaptor GRB4 binds the cytoplasmic tail of ENFB1. The SH3 domains of these adaptor proteins can in turn recruit a number of SH3-binding partners (e.g. AXIN, PAK1, FAK and Paxillin) to the EFNB1 signaling complex and participate in propagating the reverse signal in a complex manner (Cowan & Henkemeyer 2001). The diversity of EFN–EPH signaling functions is thus the product of the ability of EFN–EPH to signal in both a forward and reverse

manner and the presence of crosstalk between the several EFN–EPH pathways, non-EFN–EPH signaling pathways (e.g. the fibroblast growth factor pathway; [Sawada *et al.* 2010](#)) and different adaptor proteins. Thus, dissecting intracellular signaling pathway crosstalk among different cell types presents a challenge in characterizing EFN–EPH effects.

Additionally, ligand and receptor functions can be diversified and adjusted by higher order ligand and receptor associations resulting from clustering. Clustering can involve the extracellular receptor domain as well as the intracellular RTK and SAM domains. Homo-oligomerization can follow interactions between EPHs that follow the formation of the initial ligand–receptor tetramer. Additionally, interfamilial hetero-oligomers have been observed to cluster and produce different activation or inhibition states according to the relative levels of expression within the cluster ([Janes *et al.* 2011](#), [Jurek *et al.* 2016](#)). Conformational changes following EPH binding, while limited when compared to other RTKs, might explain some of the interfamilial binding between ligands and receptors ([Janes *et al.* 2012](#)). The role of proteolytic cleavage in further regulating EFN–EPH signaling has been reviewed elsewhere ([Atapattu *et al.* 2014](#)). Additionally, splice variants in EPHA7 have been observed; kinase domain-deficient variants bias receptor function from repulsion toward adhesion ([Holmberg *et al.* 2000](#)). Considering the wide array of receptors, the ability to signal in forward and reverse directions, and the extracellular and intracellular variations, modulation of the EFN–EPH system of cell signaling is indeed complex.

Mechanisms of EFN–EPH signaling in skeletal development

The EFNs and EPHs have been best characterized during the development of various murine tissues. Global knockout mouse studies have demonstrated that EFNA2 and EPHA7 mediate neural development by inhibiting proliferation. EFNB2 patterns the somites and regulates neural cell development ([Davy & Soriano 2007](#)). Neurogenesis, axonal guidance and vasculogenesis are regulated by different EFNs and EPHs through both forward and reverse signaling ([Zhang & Hughes 2006](#), [Wilkinson 2014](#)). Given their established functions in cell motility and adherence, it is not surprising that members of both the A and B families of ligands and receptors have been associated with neo-angiogenesis and invasiveness of several types of tumors ([Brantley-Sieders & Chen 2004](#),

[Kumar *et al.* 2006](#)), with deleterious effects attributed to their expression levels in the affected tissues ([Campbell & Robbins 2008](#)).

A variety of EFNs and EPHs are expressed in various tissues during the normal inflammatory response to injury and in chronic inflammation, where they mediate diverse processes such as vascular permeability and cell motility ([Coulthard *et al.* 2012](#)). EFNB1 and EPHB2 expression is upregulated during skin wound repair and drives the re-epithelialization necessary for healing through the downregulation of tight junctions, the release of adherens and the reduction in actinomyosin tension ([Nunan *et al.* 2015](#)). EFNs and EPHs mediate growth factor-regulated angiogenesis during development, and they would also be expected to mediate the repair of skeletal tissues in a similar fashion.

The EFNs and EPHs are widely expressed in skeletal tissues, as they are in most tissues. The *EFNA2*, *EPHA2*, *EPHA4*, *EFNB1* and *EFNB2* genes are expressed in osteoclasts induced to differentiate *in vitro* ([Irie *et al.* 2009](#)); several ligand and receptor genes of both the A and B families are expressed in differentiating osteoblasts *in vitro* ([Zhao *et al.* 2006](#), [Matsuo & Otaki 2012](#)). *In vivo*, *EFNB2* gene and *EFNB2* protein expression in osteoblasts and osteoclasts was promoted by PTH and parathyroid hormone-related peptide (PTHrP). The authors suggest that the anabolic effect of PTH and PTHrP could be mediated by *EFNB2* action on osteoblasts that express *EPHB* ([Allan *et al.* 2008](#)). These characteristics of EFN–EPH expression have important implications for the maintenance of homeostasis between osteoblasts and osteoclasts and the balance between bone formation and bone resorption.

Bone lineage motility and differentiation are regulated by EFN–EPH binding. *EFNB2* and *EPHB4* interactions mediate the mobilization from the bone marrow to the blood of *EFNB2*-expressing bone marrow hematopoietic precursors through the *EPHB4*-expressing sinusoidal cells. Antibody-dependent inhibition of this interaction and dominant-negative *EPHB4* receptor studies established that the mechanism was dependent on forward cell–cell signaling ([Kwak *et al.* 2016](#)). *In vitro* spreading and migration assays on human mesenchymal stem cells (MSCs) using soluble *EFNB* and *EPHB* established that forward signaling through *EPHB2* promoted MSC spreading, but reverse signaling through *EFNB* inhibited MSC attachment and *EFNB1* and *EFNB2* ([Arthur *et al.* 2011](#)). *EFNB* family regulation of bone marrow MSCs is important for several aspects of bone formation and possibly bone repair.

It was the observation that spontaneous *EFN* and *EPH* mutations resulted in abnormalities in embryonic skeletal development that first implicated EFN–EPH as important regulators in bone. Additional studies in mice with targeted deletions of different *EFN* and *EPH* genes have further established the importance of EFN–EPH signaling in skeletal development and characterized its effects in the regulation of bone cell differentiation as described below.

The developmental functions of EFN–EPH in the skeleton have been best described in craniofacial patterning abnormalities. *EPHA4* has been demonstrated in *Twist1*- and *EPHA4*-mutant mice to mediate *Twist1* regulation of osteogenic cell migration to the coronal sutures and to then exclude these cells from the sutures. A failure of *EPHA4* signaling produced craniosynostosis in these models (Ting *et al.* 2009). In mice with *EFNB1* mutations, it is believed that X-linked mosaicism of *EFNB1* impaired cell sorting. Using signaling-deficient mutations, forward and reverse signaling between *EFNB1* and *EPHB*, which mediate adhesion and repulsion in mesenchymal cell condensations, was demonstrated to regulate this aspect of craniofacial development (Davy *et al.* 2004). The calvarial defect phenotype in *EFNB1* mutants was similar to that observed in neural crest cell sorting and was the result of impaired gap junction communication involving *EFNB1* in early osteogenic precursor development (Davy *et al.* 2006). Similar craniofacial abnormalities are produced by *EFNB1* signaling mutations in human pathology (Compagni *et al.* 2003). However, other studies have implicated unidirectional forward signaling in this phenotype. *EFNB1* patterning of palate development is accomplished through forward signaling interactions with *EPHB2* and *EPHB3* receptors, as demonstrated by combination *EPHB2* forward signaling-deficient mutants/*EPHB3*-knockout mice, which developed the cleft palate. The defect resided in reduced proliferation (Risley *et al.* 2009) of the palatal mesenchymal cells mediated by these *EPHB*s. Recent studies have postulated that the separation of the sutures results from *EFNB1* forward signaling mediated by Rho-associated protein kinase (ROCK). ROCK signaling modifies intracellular actin distributions and the resulting cortical tension of *EFNB1*-expressing cells, maintaining the suture separating them from non-*EFNB1*-expressing cells (O'Neill *et al.* 2016).

The *EFNA* and *EPHA* families also mediate communication between osteoblasts and osteoclasts. Interactions between *EFNA2* and *EPHA4* enhance osteoclast differentiation but inhibit osteoblast differentiation, as osteoblast differentiation was enhanced in *EPHA4*-deficient osteoblasts in response to *EFNA2*

overexpression (Irie *et al.* 2009). This effect must bias the initiation of remodeling away from bone formation, although multiple EFN–EPH interactions may mediate this communication (Fig. 2). *EFNA2* also interacts with *EPHA2* in promoting osteoclastogenesis to promote osteoporotic resorption; ovariectomy in rats increased *EFNA2*–*EPHA2* signaling, osteoclast development and trabecular bone deterioration, effects that were reduced *in vitro* by the inhibition of *EFNA2* and *EPHA2* expression and *in vivo* by estradiol treatment (Liu *et al.* 2018). These observations suggest EFN–EPH modulation as an alternative to hormone-related therapy for osteoporosis.

Studies in mice with targeted disruption of the *EPHA4* gene in osteoclasts have shown that *EPHA4* functions are diverse. *EPHA4* expression inhibited the activity but not the development of osteoclasts through the altered phosphorylation of stimulatory and inhibitory mediators of osteoclast activity (Stiffel *et al.* 2014). *EPHA5* has been determined to be an inhibitor of osteogenic development

Figure 2

A model for EFN–EPH regulation of bone cell interaction in bone development and homeostasis. Several EFNs and EPHs mediate growth plate development during bone growth. Interactions between osteoblasts (OB), osteoclasts (OC), MSCs, and chondrocytes are mediated by different ligand–receptor combinations, coordinating bone cell development and activity through forward and reverse signaling. Osteoblast development is mediated by forward signaling through *EPHB4* from *EFNB2* (Zhao *et al.* 2006) and reverse signaling through *EFNB1*/*EFNB2* from *EPHB2* (Arthur *et al.* 2011). Osteoclast development is mediated by *EFNA2* and *EPHA4* (Irie *et al.* 2009, Liu *et al.* 2018) as well as through reverse signaling from *EPHB4* through *EFNB2* (Zhao *et al.* 2006).

of bone marrow stromal cells in culture (Yamada *et al.* 2013). EPHA5 inhibition is overcome by the exogenous addition of dexamethasone (Yamada *et al.* 2016), suggesting potential interaction between a systemic hormone and a local growth factor in regulating osteogenesis, although the mechanism remains to be elucidated. Developmental studies in *Hoxa13*-knockout mice implicate EPHA7 expression in mediating *Hoxa13*-dependent mesenchymal cell adherence and chondrocyte condensations in the knockout autopods, which display digit fusions (Stadler *et al.* 2001). The EPHAs therefore participate in different aspects of skeletal development and homeostasis.

Studies in *EFNB1*-knockout mice established that EFNB1 can promote different aspects of bone homeostasis. An osteoblast (*Osx*)-specific knockout of *EFNB1* resulted in altered long bone development, with impaired trabecular and cortical bone formation. A decrease in osteoblasts and increase in osteoclast formation suggests that EFNB1 can mediate bone formation and resorption (Nguyen *et al.* 2016). Other investigations have determined the mechanism of intracellular signaling that mediate this effect. Transgenic overexpression of *EFNB1* in murine osteoblasts increased osteoblast differentiation and mineralization *in vitro*, increased *Osx* expression and trabecular bone formation *in vivo* and reduced osteoclastogenesis through EPHB2 in response to mechanical loading of the long bones (Cheng *et al.* 2013). Further studies also examined the role of EFNB1 in the osteoclast lineage and established that deletion of *EFNB1* from myeloid cells increased osteoclastogenesis. Trabecular bone was reduced in the knockout mice without changes in bone formation. *In vitro* studies implicated reverse signaling of EFNB1 through EPHB2 as a mechanism for this effect and a role for EFNB1 as a negative regulator of osteoclast differentiation (Cheng *et al.* 2012).

Deletion of *EFNB2* in osteoblasts resulted in a significant reduction in bone formation in knockout mice *in vivo* and reduced mineralization and expression of late-stage osteoblast differentiation markers *in vitro*. *EFNB2* deletion has been observed to increase apoptosis in the osteoblast lineage, suggesting yet another mode for this EFN in promoting bone formation (Tonna *et al.* 2014).

Role of EFN–EPH in cell-cell communication

Multiple EFN–EPH interactions mediate several aspects of bone development and homeostasis, but the EFNB2–EPHB4 ligand–receptor signaling pair is especially well studied in the mediation of osteoblast–osteoclast communication that maintains a homeostasis between bone formation and

bone remodeling in the skeleton (Edwards & Mundy 2008). *In vitro* and *in vivo* studies established that the EFNB2–EPHB4 ligand–receptor pair is especially important for bone homeostasis, as forward signaling from EFNB2 through EPHB4 promoted bone formation from osteoblasts, while reverse signaling from EPHB4 through EFNB2 inhibited osteoclastogenesis by suppressing NFATc1 (Zhao *et al.* 2006). In this case, an *in vivo* reduction in osteoblast development and bone formation would be expected in osteoblast marker-specific *EPHB4*-knockout mice, while an increase in osteoclast development and bone resorption functions would be expected in osteoclast marker-specific *EFNB2* knockout mice. However, the osteoclast-specific *EFNB2*-knockout mice in this same study exhibited only a slight increase in osteoclast number without a change in bone volume, osteoblast surface or BMD (Zhao *et al.* 2006). In contrast, a myeloid lineage *EFNB1*-knockout mouse also driven by *Lys2-cre* expression did present a phenotype with increased resorption (Cheng *et al.* 2012), which suggests that EFNB1 is a negative regulator of osteoclast function and that there is a redundancy in the EFNs, and possibly the EPHs, in osteoblast–osteoclast coupling. In either case, a functional demonstration of forward or reverse signaling in osteoblast–osteoclast coupling, respectively, would require that the phenotype be accompanied by a reduction in signaling from an EPHB receptor in an osteoclast-specific *EFNB* knockout or EFN-specific signaling to a specific receptor in an osteoblast-specific *EPHB* knockout.

In vitro, EFNB2 expression and EFNB2–EPHB4 interaction in response to PTH or PTHRP treatment has been associated with the differentiation of stromal cells to mineralizing osteoblasts (Allan *et al.* 2008). EPHB4 inhibition by soluble EPHB4 inhibited EFNB2–EPHB4 signaling and the expression of late-stage osteoblast differentiation markers and promoted osteoclast formation, even preventing the anabolic response to PTH. This effect required osteoblasts *in vitro*, indicating that signaling between EFNB2 and EPHB4 within the osteoblast lineage is required for osteoblast differentiation and osteoclast formation (Takyar *et al.* 2013). These results suggest that EFNB2–EPHB4 regulation of bone formation and resorption might be complicated by the expression and function of multiple EFNs and EPHs during the development of the bone cell lineages. Indeed, this interaction extends to skeletal pathology in the adult; elevated EPHB4 expression in osteoarthritis chondrocytes was reduced by an *in vitro* application of EFNB2, which increased *Col2* gene expression, a marker of chondrocyte development and decreased markers of bone resorption (Kwan Tat *et al.* 2009).

In addition to its interactions with EPHB4 in bone homeostasis, EFNB2 is important in calvarial bone

formation (Benson *et al.* 2012). Embryonic expression of EFN2 is found in the calvarial sutures and periosteum but expression is confined to the sutures of the adult murine calvariae. It promotes the expression of bone formation markers *in vitro* and calvarial bone formation in organ culture, possibly through EPHB1 and EPHB2 signaling. *In vivo*, EFN2 might mediate bone formation through EPHs outside of the EFN2–EPHB4 signaling circuit, as it promotes bone formation in the calvariae, where EPHB4, its preferred receptor, is not expressed.

Other EFN ligand–receptor signaling combinations could regulate osteoblast functions through osteoclasts. The anti-resorptive alendronate has been demonstrated to increase the expression of eFN1, EPHB1 and EPHB3 in mice and decrease bone sialoprotein and osteonectin, markers of bone formation that were dependent on pre-osteoclasts. Because the expression of EFN1 and these EPHs was present on osteoclasts and osteoblasts, respectively, the authors conclude that EFN1 expressed in osteoclasts inhibits osteoblast differentiation (Shimizu *et al.* 2012). This signaling appears similar to that of EFN2 and EPHB4 in maintaining bone homeostasis (Zhao *et al.* 2006) and suggests a degree of functional redundancy among the EFNs and EPHs.

EFN–EPH functions have also been associated with bone repair. In addition to its role in calvarial bone formation during development, EFN2 expression is elevated at sites of calvarial bone injury, suggesting regulation of the bone formation phase of bone repair (Benson *et al.* 2012). The *Col1*-mediated overexpression of transgenic *EPHB4* in osteoblasts in a murine model of femur fracture healing increased osteogenic progenitors and decreased osteoclasts, which resulted in increased bone formation and reduced bone remodeling within the fracture callus (Arthur *et al.* 2013). These results might involve EFN2–EPHB4 signaling, as an increase in EPHB4 would be expected to decrease osteoclastogenesis predicted by reverse signaling through EFN2 and thereby increase bony callus formation (Zhao *et al.* 2006). Alternatively, EPHB4 might function by forward signaling from different EFNs. Thus, interaction between EFNs in one cell type and their receptors in a different cell type can lead to enrichment of various cell types that contribute to key cellular processes involved in fracture repair.

Interactions between IGF and EFN–EPH signaling

There is now substantial evidence in the literature to suggest that interactions between chondrocytes, osteoblasts and osteoclasts are important in the regulation of bone

metabolism. In terms of molecular signals that contribute to the interactions between the various bone cell types, IGF1 and EFN–EPH signaling have received considerable attention since studies using various knockout mouse models and *in vitro* cell culture systems demonstrate that these signaling pathways are critical in bone and are required for stimulation of bone formation by a number of key anabolic agents including PTH and mechanical strain. Therefore, it is likely that IGF1 and EFN–EPH signaling pathways interact to regulate bone metabolism during normal and disease states. Accordingly, recent studies provide evidence that some of the actions of IGF1 in the skeleton are mediated via regulation of EFN–EPH signaling as described below.

Recent studies support a role for IGF1 interactions with EFN–EPH signaling in postnatal skeletal growth. Global *EPHA4*-knockout mice displayed a dramatic general reduction in body size that was gene dose-dependent in heterozygotes. Bone growth was affected; there was a reduction in the length of the epiphyseal growth plates of the long bones consistent with growth reduction and not achondroplasia. This phenotype was accompanied by low plasma IGF1 levels and markedly reduced *Igf1* mRNA in the liver and other tissues. Since GH and GHR levels were unchanged, the reduction in IGF1 production was not due to decreased GH signal. Rather, *EPHA4* forms a complex with the GHR and downstream GH effectors JAK2 and STAT5B to enhance IGF1 production in response to GH. This effect was largely JAK2-dependent, although some direct effect on STAT5B was observed. Thus, in the absence of *EPHA4*, decreased production of IGF1 resulted in a small body size (Jing *et al.* 2012).

Further molecular studies characterized the binding of JAK2 and *EPHA4* to the GHR, the phosphorylation status of *EPHA4*, GHR, JAK2 and STAT5B resulting from their mutual interactions, and the subsequent nuclear translocation of STAT5B. While GH canonically activates STAT5B via the GHR and JAK2, EFN–*EPHA4* signaling was found to induce STAT5B activation independent of JAK2. The GHR was required for this JAK2-independent activation of STAT5B, although its precise role remains to be elucidated (Sawada *et al.* 2017). These studies reveal a global role for *EPHA4* functions in the body, in contrast to tissue-specific knockout models that demonstrate its regulation of osteoclast functions.

IGF1 is an important regulator of endochondral bone formation, and its functions have been demonstrated to be mediated by EFN2–EPHB4 signaling (Wang *et al.* 2014). *In vivo*, the normal expression was reduced in *Igf1*-knockout mice and in the growth plates of *Col2*- or *Osx*-specific *Igf1r*-knockout mice (Wang *et al.* 2015).

In vitro, inhibition of EFN2 by deletion or EPHB4 expression with a specific receptor inhibitor reduced the expression of osteogenic markers in response to IGF1. *In vitro* blocking of EPHB2 and EPHB4 interaction through specific inhibition of EFN2 or EPHB4 also reduced the development of osteoclasts and osteoblasts, respectively, in response to IGF1 (Fig. 3). With respect to chondrocytes, *in vitro* inhibition of the EFN2–EPHB4 interaction reduced the expression of markers of chondrocyte and osteoclast development in response to IGF1. These results provide strong evidence for EFN2–EPHB4 functions in cell–cell contact for IGF1-induced bone development and for intermittent PTH-induced bone development, as PTH regulates IGF1 functions.

There is also now evidence in the literature that IGF1 can interact with EFN–EPH signaling to regulate cellular processes. For example, IGF1 has been shown to regulate EFN1 functions following tooth injury. Tooth injury in mice with dentin matrix protein (*Dmp*)-1-driven deletion of *Igf1r* demonstrate reduced *EFNB1* expression and impaired tooth repair. In response to the dental pulp capping procedure, *Igf1* expression was increased. However, specific inhibition of IGF1R signaling pathways revealed that *EFNB1* and *EPHB2* expression was mediated by different pathways. EFN1 and EPHB2 signaling therefore mediate IGF1 functions during tooth repair (Matsumura *et al.* 2017).

Skeletal myogenesis requires the activation of the PI3K/Akt cascade but is inhibited by the ERK1/2 cascade. IGF1 induces myogenesis; however, IGF1 is known to activate both the PI3K/Akt and ERK1/2 cascades.

Figure 3

A model of the interaction of IGF1 and EFN–EPH signaling in skeletal metabolism. IGF1 can act directly on chondrocytes and osteoblasts, increasing EFN2–EPHB4 signaling and leading to differentiation of each cell type by increasing expression of key transcription factors. Through reverse signaling, EFN2–EPHB4 interaction can decrease NFATC1 expression in osteoclast precursors and inhibit formation of differentiated, mature multinucleated osteoclasts (Zhao *et al.* 2006, Kwan Tat *et al.* 2009, Wang *et al.* 2015).

EFNA–EPHA signaling downregulates the Ras/ERK1/2 pathway. *In vitro* activation of EFNA1 enhanced the ability of IGF1 to increase myogenic differentiation, an effect which was dependent upon the ability of EPHA to decrease ERK1/2 signaling. Furthermore, the ability of IGF1 to induce myogenesis was inhibited by downregulation of EFNA–EPHA, an effect which was rescued by inactivation of ERK1/2. EFNA–EPHA-mediated suppression of ERK1/2 is thus required for IGF1 to induce myogenesis (Minami *et al.* 2011).

Studies of protein associations also have benefited from the development of databases that predict interactions between proteins. Significant changes in gene expression obtained from microarray data can be merged with protein–protein interaction (PPI) databases to identify proteins that might interact to regulate the condition. By merging miRNA microarray data and PPI predictions, IGF1 and EPHA4 proteins also were identified within two separate subnetworks of interacting proteins in OA (Wang *et al.* 2013). Although a functional connection between IGF1 and EPHA4 was not investigated, their presence in the OA PPI network suggests an interaction between them is possible and that such a database approach might be valuable in identifying candidate proteins that could interact with large and widely expressed families of genes, such as the EFNs and the EPHs.

Recent investigations have only begun to characterize the interactions of IGF1, EFNs and EPHs in the skeleton. Given the importance of IGF1 as a growth factor in several tissues and the widespread expression and importance of the EFNs and EPHs in tissue development, it is probable the EFN and EPH interactions with IGF1, as well as other growth factors, are extensive and remain to be elucidated.

Summary

The IGF1 and EFN–EPH signaling pathways are both critical regulators of bone cell function and skeletal development and maintenance. Many different signals and factors regulate IGF1 signaling at the systemic and local levels, making it a point of integration for several different pathways which induce bone growth and maintenance. EFN–EPH signaling is a complex system which, particularly through cell–cell interactions, contributes to the development and differentiation of many bone cell types. Thus, the fact that recent studies have established the interaction between these two signaling pathways opens a vast array of new opportunities for investigation into the mechanisms of and potential therapies for skeletal conditions such as osteoporosis and fracture repair.

Future research directions

While the role of IGF1 signaling in bone has been studied in great detail, the role of IGF2 in human bone metabolism remains to be elucidated. In rodents, IGF2 is primarily a fetal growth factor, and its expression declines during postnatal growth while IGF1 expression increases. In contrast, IGF2 is expressed at higher levels in adult human tissues including bone. The question of whether IGF2 participates significantly in adult bone metabolism and osteoporosis pathogenesis thus remains to be established. Furthermore, while recent evidence suggests a role for IGF1 in age-related bone loss and osteoporosis, the extent of its contribution and usefulness as an anabolic therapy for osteoporosis deserve further consideration and study. Additionally, work remains to be done in elucidating the particular roles of the various EFNs and EPHs in each of the bone cell types and their contributions to the regulation of skeletal growth. The precise roles of EFN–EPH and IGF1 signaling in fracture repair also remain to be uncovered. Finally, the mechanisms by which IGF1 and EFN–EPH signaling interact to regulate skeletal metabolism and growth must be determined with an emphasis toward developing novel strategies for treatment of osteoporosis and bone repair.

Declaration of interest

The authors declare that there is no conflict of interest that could be perceived as prejudicing the impartiality of this review.

Funding

S M is a recipient of a Senior Research Career Scientist Award from the US Department of Veterans Affairs. This work was supported by funding from a National Institute of Arthritis and Musculoskeletal and Skin Diseases R01 grant (AR048139) to S M, a Veterans Administration BLR&D merit review grant (101-BX-002519) to C H R, and the National Institutes of Health IMSD grant to the LLU Center for Health Disparities and Molecular Medicine (2 R25 GM060507).

References

- Allan EH, Häusler KD, Wei T, Gooi JH, Quinn JMW, Crimeen-Irwin B, Pompolo S, Sims NA, Gillespie MT, Onyia JE, et al. 2008 EphrinB2 regulation by PTH and PTHrP revealed by molecular profiling in differentiating osteoblasts. *Journal of Bone and Mineral Research* **23** 1170–1181. (<https://doi.org/10.1359/jbmr.080324>)
- Ammann P, Bourrin S, Bonjour JP, Meyer JM & Rizzoli R 2000 Protein undernutrition-induced bone loss is associated with decreased IGF-I levels and estrogen deficiency. *Journal of Bone and Mineral Research* **15** 683–690. (<https://doi.org/10.1359/jbmr.2000.15.4.683>)
- Arthur A, Zannettino A, Panagopoulos R, Koblar SA, Sims NA, Stylianou C, Matsuo K & Gronthos S 2011 EphB/ephrin-B interactions mediate human MSC attachment, migration and osteochondral differentiation. *Bone* **48** 533–542. (<https://doi.org/10.1016/j.bone.2010.10.180>)
- Arthur A, Panagopoulos RA, Cooper L, Menicanin D, Parkinson IH, Codrington JD, Vandyke K, Zannettino ACW, Koblar SA, Sims NA, et al. 2013 EphB4 enhances the process of endochondral ossification and inhibits remodeling during bone fracture repair. *Journal of Bone and Mineral Research* **28** 926–935. (<https://doi.org/10.1002/jbmr.1821>)
- Atapattu L, Lackmann M & Janes PW 2014 The role of proteases in regulating Eph/ephrin signaling. *Cell Adhesion and Migration* **8** 294–307. (<https://doi.org/10.4161/19336918.2014.970026>)
- Bagi CM, Brommage R, Deleon L, Adams S, Rosen D & Sommer A 1994 Benefit of systemically administered rhIGF-I and rhIGF-I/IGFBP-3 on cancellous bone in ovariectomized rats. *Journal of Bone and Mineral Research* **9** 1301–1312. (<https://doi.org/10.1002/jbmr.5650090820>)
- Benbassat CA, Maki KC & Unterman TG 1997 Circulating levels of insulin-like growth factor (IGF) binding protein-1 and -3 in aging men: relationships to insulin, glucose, IGF, and dehydroepiandrosterone sulfate levels and anthropometric measures. *Journal of Clinical Endocrinology and Metabolism* **82** 1484–1491. (<https://doi.org/10.1210/jcem.82.5.3930>)
- Benson MD, Opperman LA, Westerlund J, Fernandez CR, San Miguel S, Henkemeyer M & Chenuaux G 2012 Ephrin-B stimulation of calvarial bone formation. *Developmental Dynamics* **241** 1901–1910. (<https://doi.org/10.1002/dvdy.23874>)
- Bikle DD, Sakata T, Leary C, Elalieh H, Ginzinger D, Rosen CJ, Beamer W, Majumdar S & Halloran BP 2002 Insulin-like growth factor I is required for the anabolic actions of parathyroid hormone on mouse bone. *Journal of Bone and Mineral Research* **17** 1570–1578. (<https://doi.org/10.1359/jbmr.2002.17.9.1570>)
- Bonjour J-P 2016 The dietary protein, IGF-I, skeletal health axis. *Hormone Molecular Biology and Clinical Investigation* **28** 39–53. (<https://doi.org/10.1515/hmbci-2016-0003>)
- Bonjour J-P, Chevalley T, Rizzoli R & Ferrari S 2007 Gene-environment interactions in the skeletal response to nutrition and exercise during growth. *Medicine and Sport Science* **51** 64–80. (<https://doi.org/10.1159/000103005>)
- Boonen S, Mohan S, Dequeker J, Aerssens J, Vanderschueren D, Verbeke G, Broos P, Bouillon R & Baylink DJ 1999 Down-regulation of the serum stimulatory components of the insulin-like growth factor (IGF) system (IGF-I, IGF-II, IGF binding protein [BP]-3, and IGFBP-5) in age-related (type II) femoral neck osteoporosis. *Journal of Bone and Mineral Research* **14** 2150–2158. (<https://doi.org/10.1359/jbmr.1999.14.12.2150>)
- Bourrin S, Ammann P, Bonjour JP & Rizzoli R 2000 Dietary protein restriction lowers plasma insulin-like growth factor I (IGF-I), impairs cortical bone formation, and induces osteoblastic resistance to IGF-I in adult female rats. *Endocrinology* **141** 3149–3155. (<https://doi.org/10.1210/endo.141.9.7633>)
- Brantley-Sieders DM & Chen J 2004 Eph receptor tyrosine kinases in angiogenesis: from development to disease. *Angiogenesis* **7** 17–28. (<https://doi.org/10.1023/B:AGEN.0000037340.33788.87>)
- Burge R, Dawson-Hughes B, Solomon DH, Wong JB, King A & Tosteson A 2007 Incidence and economic burden of osteoporosis-related fractures in the United States, 2005–2025. *Journal of Bone and Mineral Research* **22** 465–475. (<https://doi.org/10.1359/jbmr.061113>)
- Campbell TN & Robbins SM 2008 The Eph receptor/ephrin system: an emerging player in the invasion game. *Current Issues in Molecular Biology* **10** 61–66.
- Canalis E 2005 Mechanisms of glucocorticoid action in bone. *Current Osteoporosis Reports* **3** 98–102. (<https://doi.org/10.1007/s11914-005-0017-7>)
- Cayuso J, Xu Q & Wilkinson DG 2015 Mechanisms of boundary formation by Eph receptor and ephrin signaling. *Developmental Biology* **401** 122–131. (<https://doi.org/10.1016/j.ydbio.2014.11.013>)
- Centrella M, McCarthy TL & Canalis E 1990 Receptors for insulin-like growth factors-I and -II in osteoblast-enriched cultures from fetal rat bone. *Endocrinology* **126** 39–44. (<https://doi.org/10.1210/endo-126-1-39>)

- Chen TL, Chang LY, Bates RL & Perlman AJ 1991 Dexamethasone and 1,25-dihydroxyvitamin D3 modulation of insulin-like growth factor-binding proteins in rat osteoblast-like cell cultures. *Endocrinology* **128** 73–80. (<https://doi.org/10.1210/endo-128-1-73>)
- Chen C-Y, Tseng K-Y, Lai Y-L, Chen Y-S, Lin F-H & Lin S 2017 Overexpression of insulin-like growth factor 1 enhanced the osteogenic capability of aging bone marrow mesenchymal stem cells. *Theranostics* **7** 1598–1611. (<https://doi.org/10.7150/thno.16637>)
- Cheng S, Zhao SL, Nelson B, Kesavan C, Qin X, Wergedal J, Mohan S & Xing W 2012 Targeted disruption of ephrin B1 in cells of myeloid lineage increases osteoclast differentiation and bone resorption in mice. *PLoS ONE* **7** e32887. (<https://doi.org/10.1371/journal.pone.0032887>)
- Cheng S, Kesavan C, Mohan S, Qin X, Alarcon CM, Wergedal J & Xing W 2013 Transgenic overexpression of ephrin b1 in bone cells promotes bone formation and an anabolic response to mechanical loading in mice. *PLoS ONE* **8** e69051. (<https://doi.org/10.1371/journal.pone.0069051>)
- Cheng S, Xing W, Pourteymoor S & Mohan S 2016 Effects of thyroxine (T4), 3,5,3'-triiodo-L-thyronine (T3) and their metabolites on osteoblast differentiation. *Calcified Tissue International* **99** 435–442. (<https://doi.org/10.1007/s00223-016-0159-x>)
- Chevalley T, Strong DD, Mohan S, Baylink D & Linkhart TA 1996 Evidence for a role for insulin-like growth factor binding proteins in glucocorticoid inhibition of normal human osteoblast-like cell proliferation. *European Journal of Endocrinology* **134** 591–601. (<https://doi.org/10.1530/eje.0.1340591>)
- Chevalley T, Bonjour J-P, Ferrari S & Rizzoli R 2008 High-protein intake enhances the positive impact of physical activity on BMC in prepubertal boys. *Journal of Bone and Mineral Research* **23** 131–142. (<https://doi.org/10.1359/jbmr.070907>)
- Christians JK, de Zwaan DR & Fung SHY 2013 Pregnancy associated plasma protein A2 (PAPP-A2) affects bone size and shape and contributes to natural variation in postnatal growth in mice. *PLoS ONE* **8** e56260. (<https://doi.org/10.1371/journal.pone.0056260>)
- Christoforidis A, Maniadaki I & Stanhope R 2005 Growth hormone/insulin-like growth factor-1 axis during puberty. *Pediatric Endocrinology Reviews* **3** 5–10.
- Compagni A, Logan M, Klein R & Adams RH 2003 Control of skeletal patterning by ephrinB1-EphB interactions. *Developmental Cell* **5** 217–230. ([https://doi.org/10.1016/S1534-5807\(03\)00198-9](https://doi.org/10.1016/S1534-5807(03)00198-9))
- Conover CA 1995 Insulin-like growth factor binding protein proteolysis in bone cell models. *Progress in Growth Factor Research* **6** 301–309. ([https://doi.org/10.1016/0955-2235\(95\)00032-1](https://doi.org/10.1016/0955-2235(95)00032-1))
- Corpas E, Harman SM & Blackman MR 1993 Human growth hormone and human aging. *Endocrine Reviews* **14** 20–39. (<https://doi.org/10.1210/edrv-14-1-20>)
- Coulthard MG, Morgan M, Woodruff TM, Arumugam TV, Taylor SM, Carpenter TC, Lackmann M & Boyd AW 2012 Eph/Ephrin signaling in injury and inflammation. *American Journal of Pathology* **181** 1493–1503. (<https://doi.org/10.1016/j.ajpath.2012.06.043>)
- Cowan CA & Henkemeyer M 2001 The SH2/SH3 adaptor Grb4 transduces B-ephrin reverse signals. *Nature* **413** 174–179. (<https://doi.org/10.1038/35093123>)
- Davy A & Soriano P 2007 Ephrin-B2 forward signaling regulates somite patterning and neural crest cell development. *Developmental Biology* **304** 182–193. (<https://doi.org/10.1016/j.ydbio.2006.12.028>)
- Davy A, Gale NW, Murray EW, Klinghoffer RA, Soriano P, Feuerstein C & Robbins SM 1999 Compartmentalized signaling by GPI-anchored ephrin-A5 requires the Fyn tyrosine kinase to regulate cellular adhesion. *Genes and Development* **13** 3125–3135.
- Davy A, Aubin J & Soriano P 2004 Ephrin-B1 forward and reverse signaling are required during mouse development. *Genes and Development* **18** 572–583. (<https://doi.org/10.1101/gad.1171704>)
- Davy A, Bush JO & Soriano P 2006 Inhibition of gap junction communication at ectopic Eph/ephrin boundaries underlies craniofrontonasal syndrome. *PLoS Biology* **4** e315. (<https://doi.org/10.1371/journal.pbio.0040315>)
- Dawson-Hughes B, Harris SS, Rasmussen H, Song L & Dallal GE 2004 Effect of dietary protein supplements on calcium excretion in healthy older men and women. *Journal of Clinical Endocrinology and Metabolism* **89** 1169–1173. (<https://doi.org/10.1210/jc.2003-031466>)
- DeMambro VE, Le PT, Guntur AR, Maridas DE, Canalis E, Nagano K, Baron R, Clemmons DR & Rosen CJ 2015 Igfbp2 deletion in ovariectomized mice enhances energy expenditure but accelerates bone loss. *Endocrinology* **156** 4129–4140. (<https://doi.org/10.1210/en.2014-1452>)
- Denger S, Bähr-Ivacevic T, Brand H, Reid G, Blake J, Seifert M, Lin C-Y, May K, Benes V, Liu ET, *et al.* 2008 Transcriptome profiling of estrogen-regulated genes in human primary osteoblasts reveals an osteoblast-specific regulation of the insulin-like growth factor binding protein 4 gene. *Molecular Endocrinology* **22** 361–379. (<https://doi.org/10.1210/me.2007-0292>)
- Devlin RD, Du Z, Buccilli V, Jorgetti V & Canalis E 2002 Transgenic mice overexpressing insulin-like growth factor binding protein-5 display transiently decreased osteoblastic function and osteopenia. *Endocrinology* **143** 3955–3962. (<https://doi.org/10.1210/en.2002-220129>)
- Edwards CM & Mundy GR 2008 Eph receptors and ephrin signaling pathways: a role in bone homeostasis. *International Journal of Medical Sciences* **5** 263–272. (<https://doi.org/10.7150/ijms.5.263>)
- Fan Y, Menon RK, Cohen P, Hwang D, Clemens T, DiGirolamo DJ, Kopchick JJ, Le Roith D, Trucco M & Sperling MA 2009 Liver-specific deletion of the growth hormone receptor reveals essential role of growth hormone signaling in hepatic lipid metabolism. *Journal of Biological Chemistry* **284** 19937–19944. (<https://doi.org/10.1074/jbc.M109.014308>)
- Gabbitas B & Canalis E 1996 Retinoic acid stimulates the transcription of insulin-like growth factor binding protein-6 in skeletal cells. *Journal of Cellular Physiology* **169** 15–22. ([https://doi.org/10.1002/\(SICI\)1097-4652\(199610\)169:1<15::AID-JCP2>3.0.CO;2-H](https://doi.org/10.1002/(SICI)1097-4652(199610)169:1<15::AID-JCP2>3.0.CO;2-H))
- Gaffney-Stomberg E, Insogna KL, Rodriguez NR & Kerstetter JE 2009 Increasing dietary protein requirements in elderly people for optimal muscle and bone health. *Journal of the American Geriatrics Society* **57** 1073–1079. (<https://doi.org/10.1111/j.1532-5415.2009.02285.x>)
- Gillberg P, Johansson AG, Blum WF, Groth T & Ljunghall S 2001 Growth hormone secretion and sensitivity in men with idiopathic osteoporosis. *Calcified Tissue International* **68** 67–73. (<https://doi.org/10.1007/BF02678143>)
- Gillberg P, Olofsson H, Mallmin H, Blum WF, Ljunghall S & Nilsson AG 2002 Bone mineral density in femoral neck is positively correlated to circulating insulin-like growth factor (IGF)-I and IGF-binding protein (IGFBP)-3 in Swedish men. *Calcified Tissue International* **70** 22–29. (<https://doi.org/10.1007/s002230020048>)
- Govoni KE, Baylink DJ & Mohan S 2005 The multi-functional role of insulin-like growth factor binding proteins in bone. *Pediatric Nephrology* **20** 261–268. (<https://doi.org/10.1007/s00467-004-1658-y>)
- Govoni KE, Wergedal JE, Florin L, Angel P, Baylink DJ & Mohan S 2007a Conditional deletion of insulin-like growth factor-I in collagen type 1alpha2-expressing cells results in postnatal lethality and a dramatic reduction in bone accretion. *Endocrinology* **148** 5706–5715. (<https://doi.org/10.1210/en.2007-0608>)
- Govoni KE, Lee SK, Chung YS, Behringer RR, Wergedal JE, Baylink DJ & Mohan S 2007b Disruption of insulin-like growth factor-I expression in type 1Ialpha collagen-expressing cells reduces bone length and width in mice. *Physiological Genomics* **30** 354–362. (<https://doi.org/10.1152/physiolgenomics.00022.2007>)
- Gremion G, Rizzoli R, Slosman D, Theintz G & Bonjour JP 2001 Oligo-amenorrheic long-distance runners may lose more bone in spine than in femur. *Medicine and Science in Sports and Exercise* **33** 15–21. (<https://doi.org/10.1097/00005768-200101000-00004>)

- Grinspoon S, Thomas E, Pitts S, Gross E, Mickley D, Miller K, Herzog D & Klibanski A 2000 Prevalence and predictive factors for regional osteopenia in women with anorexia nervosa. *Annals of Internal Medicine* **133** 790–794. (<https://doi.org/10.7326/0003-4819-133-10-200011210-00011>)
- Gross TS, Srinivasan S, Liu CC, Clemens TL & Bain SD 2002 Noninvasive loading of the murine tibia: an in vivo model for the study of mechanotransduction. *Journal of Bone and Mineral Research* **17** 493–501. (<https://doi.org/10.1359/jbmr.2002.17.3.493>)
- Hayden JM, Strong DD, Baylink DJ, Powell DR, Sampath TK & Mohan S 1997 Osteogenic protein-1 stimulates production of insulin-like growth factor binding protein-3 nuclear transcripts in human osteosarcoma cells. *Endocrinology* **138** 4240–4247. (<https://doi.org/10.1210/endo.138.10.5457>)
- Holmberg J, Clarke DL & Frisén J 2000 Regulation of repulsion versus adhesion by different splice forms of an Eph receptor. *Nature* **408** 203–206. (<https://doi.org/10.1038/35041577>)
- Honda Y, Landale EC, Strong DD, Baylink DJ & Mohan S 1996 Recombinant synthesis of insulin-like growth factor-binding protein-4 (IGFBP-4): development, validation, and application of a radioimmunoassay for IGFBP-4 in human serum and other biological fluids. *Journal of Clinical Endocrinology and Metabolism* **81** 1389–1396. (<https://doi.org/10.1210/jcem.81.4.8636339>)
- Irie N, Takada Y, Watanabe Y, Matsuzaki Y, Naruse C, Asano M, Iwakura Y, Suda T & Matsuo K 2009 Bidirectional signaling through ephrinA2-EphA2 enhances osteoclastogenesis and suppresses osteoblastogenesis. *Journal of Biological Chemistry* **284** 14637–14644. (<https://doi.org/10.1074/jbc.M807598200>)
- Janes PW, Griesshaber B, Atapattu L, Nievergall E, Hii LL, Mensinga A, Chheang C, Day BW, Boyd AW, Bastiaens PI, et al. 2011 Eph receptor function is modulated by heterooligomerization of A and B type Eph receptors. *Journal of Cell Biology* **195** 1033–1045. (<https://doi.org/10.1083/jcb.201104037>)
- Janes PW, Nievergall E & Lackmann M 2012 Concepts and consequences of Eph receptor clustering. *Seminars in Cell and Developmental Biology* **23** 43–50. (<https://doi.org/10.1016/j.semcdb.2012.01.001>)
- Jiang J, Lichtler AC, Gronowicz GA, Adams DJ, Clark SH, Rosen CJ & Kream BE 2006 Transgenic mice with osteoblast-targeted insulin-like growth factor-I show increased bone remodeling. *Bone* **39** 494–504. (<https://doi.org/10.1016/j.bone.2006.02.068>)
- Jing X, Miyajima M, Sawada T, Chen Q, Iida K, Furushima K, Arai D, Chihara K & Sakaguchi K 2012 Crosstalk of humoral and cell-cell contact-mediated signals in postnatal body growth. *Cell Reports* **2** 652–665. (<https://doi.org/10.1016/j.celrep.2012.08.021>)
- Jones JI & Clemmons DR 1995 Insulin-like growth factors and their binding proteins: biological actions. *Endocrine Reviews* **16** 3–34. (<https://doi.org/10.1210/edrv-16-1-3>)
- Jurek A, Genander M, Kundu P, Catchpole T, He X, Strååt K, Sabelström H, Xu N-J, Pettersson S, Henkemeyer M, et al. 2016 Eph receptor interclass cooperation is required for the regulation of cell proliferation. *Experimental Cell Research* **348** 10–22. (<https://doi.org/10.1016/j.yexcr.2016.08.017>)
- Kanzaki S, Hilliker S, Baylink DJ & Mohan S 1994 Evidence that human bone cells in culture produce insulin-like growth factor-binding protein-4 and -5 proteases. *Endocrinology* **134** 383–392. (<https://doi.org/10.1210/endo.134.1.7506211>)
- Kapur S, Mohan S, Baylink DJ & Lau K-HW 2005 Fluid shear stress synergizes with insulin-like growth factor-I (IGF-I) on osteoblast proliferation through integrin-dependent activation of IGF-I mitogenic signaling pathway. *Journal of Biological Chemistry* **280** 20163–20170. (<https://doi.org/10.1074/jbc.M501460200>)
- Kassem M, Brixen K, Blum W, Mosekilde L & Eriksen EF 1994 No evidence for reduced spontaneous or growth-hormone-stimulated serum levels of insulin-like growth factor (IGF)-I, IGF-II or IGF binding protein 3 in women with spinal osteoporosis. *European Journal of Endocrinology* **131** 150–155. (<https://doi.org/10.1530/eje.0.1310150>)
- Kesavan C, Wergedal JE, Lau K-HW & Mohan S 2011 Conditional disruption of IGF-I gene in type 1α collagen-expressing cells shows an essential role of IGF-I in skeletal anabolic response to loading. *American Journal of Physiology: Endocrinology and Metabolism* **301** E1191–E1197. (<https://doi.org/10.1152/ajpendo.00440.2011>)
- Knutsen R, Honda Y, Strong DD, Sampath TK, Baylink DJ & Mohan S 1995 Regulation of insulin-like growth factor system components by osteogenic protein-1 in human bone cells. *Endocrinology* **136** 857–865. (<https://doi.org/10.1210/endo.136.3.7532581>)
- Kumar SR, Singh J, Xia G, Krasnoperov V, Hassanieh L, Ley EJ, Sehnert J, Kumar NG, Hawes D, Press MF, et al. 2006 Receptor tyrosine kinase EphB4 is a survival factor in breast cancer. *American Journal of Pathology* **169** 279–293. (<https://doi.org/10.2353/ajpath.2006.050889>)
- Kveiborg M, Flyvbjerg A, Eriksen EF & Kassem M 2001 1,25-Dihydroxyvitamin D3 stimulates the production of insulin-like growth factor-binding proteins-2, -3 and -4 in human bone marrow stromal cells. *European Journal of Endocrinology* **144** 549–557. (<https://doi.org/10.1530/eje.0.1440549>)
- Kwak H, Salvucci O, Weigert R, Martinez-Torrecuadrada JL, Henkemeyer M, Poulos MG, Butler JM & Tosato G 2016 Sinusoidal ephrin receptor EPHB4 controls hematopoietic progenitor cell mobilization from bone marrow. *Journal of Clinical Investigation* **126** 4554–4568. (<https://doi.org/10.1172/JCI87848>)
- Kwan Tat S, Pelletier J-P, Amiable N, Boileau C, Lavigne M & Martel-Pelletier J 2009 Treatment with ephrin B2 positively impacts the abnormal metabolism of human osteoarthritic chondrocytes. *Arthritis Research and Therapy* **11** R119. (<https://doi.org/10.1186/ar2782>)
- Lau K-HW, Kapur S, Kesavan C & Baylink DJ 2006 Up-regulation of the Wnt, estrogen receptor, insulin-like growth factor-I, and bone morphogenetic protein pathways in C57BL/6J osteoblasts as opposed to C3H/HeJ osteoblasts in part contributes to the differential anabolic response to fluid shear. *Journal of Biological Chemistry* **281** 9576–9588. (<https://doi.org/10.1074/jbc.M509205200>)
- Lau K-HW, Baylink DJ, Zhou X-D, Rodriguez D, Bonewald LE, Li Z, Ruffoni D, Müller R, Kesavan C & Sheng MH-C 2013 Osteocyte-derived insulin-like growth factor I is essential for determining bone mechanosensitivity. *American Journal of Physiology: Endocrinology and Metabolism* **305** E271–E281. (<https://doi.org/10.1152/ajpendo.00092.2013>)
- Lean JM, Jagger CJ, Chambers TJ & Chow JW 1995 Increased insulin-like growth factor I mRNA expression in rat osteocytes in response to mechanical stimulation. *American Journal of Physiology* **268** E318–E327. (<https://doi.org/10.1152/ajpendo.1995.268.2.E318>)
- Lindsey RC & Mohan S 2016 Skeletal effects of growth hormone and insulin-like growth factor-I therapy. *Molecular and Cellular Endocrinology* **432** 44–55. (<https://doi.org/10.1016/j.mce.2015.09.017>)
- Linkhart TA & Mohan S 1989 Parathyroid hormone stimulates release of insulin-like growth factor-I (IGF-I) and IGF-II from neonatal mouse calvaria in organ culture. *Endocrinology* **125** 1484–1491. (<https://doi.org/10.1210/endo-125-3-1484>)
- List EO, Berryman DE, Funk K, Jara A, Kelder B, Wang F, Stout MB, Zhi X, Sun L, White TA, et al. 2014 Liver-specific GH receptor gene-disrupted (LiGHRKO) mice have decreased endocrine IGF-I, increased local IGF-I, and altered body size, body composition, and adipokine profiles. *Endocrinology* **155** 1793–1805. (<https://doi.org/10.1210/en.2013-2086>)
- Liu Z, Mohan S & Yakar S 2016 Does the GH/IGF-1 axis contribute to skeletal sexual dimorphism? Evidence from mouse studies. *Growth Hormone and IGF Research* **27** 7–17. (<https://doi.org/10.1016/j.ghir.2015.12.004>)
- Liu L, Zhou L, Yang X, Liu Q, Yang L, Zheng C, Zhao Y, Zhang Z & Luo X 2018 17β-estradiol attenuates ovariectomy-induced bone deterioration through the suppression of the ephA2/ephrinA2

- signaling pathway. *Molecular Medicine Reports* **17** 1609–1616. (<https://doi.org/10.3892/mmr.2017.8042>)
- Locatelli V & Bianchi VE 2014 Effect of GH/IGF-1 on bone metabolism and osteoporosis. *International Journal of Endocrinology* **2014** 235060. (<https://doi.org/10.1155/2014/235060>)
- Lundin H, Sääf M, Strender L-E, Nyren S, Johansson S-E & Salminen H 2016 High serum insulin-like growth factor-binding protein 1 (IGFBP-1) is associated with high fracture risk independent of insulin-like growth factor 1 (IGF-I). *Calcified Tissue International* **99** 333–339. (<https://doi.org/10.1007/s00223-016-0152-4>)
- Malpe R, Baylink DJ, Linkhart TA, Wergedal JE & Mohan S 1997 Insulin-like growth factor (IGF)-I, -II, IGF binding proteins (IGFBP)-3, -4, and -5 levels in the conditioned media of normal human bone cells are skeletal site-dependent. *Journal of Bone and Mineral Research* **12** 423–430. (<https://doi.org/10.1359/jbmr.1997.12.3.423>)
- Martini G, Valenti R, Giovani S, Franci B, Campagna S & Nuti R 2001 Influence of insulin-like growth factor-1 and leptin on bone mass in healthy postmenopausal women. *Bone* **28** 113–117. ([https://doi.org/10.1016/S8756-3282\(00\)00408-7](https://doi.org/10.1016/S8756-3282(00)00408-7))
- Matsumura S, Quispe-Salcedo A, Schiller CM, Shin JS, Locke BM, Yakar S & Shimizu E 2017 IGF-1 mediates EphrinB1 activation in regulating tertiary dentin formation. *Journal of Dental Research* **96** 1153–1161. (<https://doi.org/10.1177/0022034517708572>)
- Matsuo K & Otaki N 2012 Bone cell interactions through Eph/ephrin: bone modeling, remodeling and associated diseases. *Cell Adhesion and Migration* **6** 148–156. (<https://doi.org/10.4161/cam.20888>)
- McCarthy TL & Centrella M 2001 Local IGF-I expression and bone formation. *Growth Hormone and IGF Research* **11** 213–219. (<https://doi.org/10.1054/ghir.2001.0236>)
- McCarthy TL, Centrella M & Canalis E 1989 Parathyroid hormone enhances the transcript and polypeptide levels of insulin-like growth factor I in osteoblast-enriched cultures from fetal rat bone. *Endocrinology* **124** 1247–1253. (<https://doi.org/10.1210/endo-124-3-1247>)
- Minami M, Koyama T, Wakayama Y, Fukuhara S & Mochizuki N 2011 EphrinA/EphA signal facilitates insulin-like growth factor-I-induced myogenic differentiation through suppression of the Ras/extracellular signal-regulated kinase 1/2 cascade in myoblast cell lines. *Molecular Biology of the Cell* **22** 3508–3519. (<https://doi.org/10.1091/mbc.E11-03-0183>)
- Misra M, Prabhakaran R, Miller KK, Goldstein MA, Mickley D, Clauss L, Lockhart P, Cord J, Herzog DB, Katzman DK, et al. 2008 Prognostic indicators of changes in bone density measures in adolescent girls with anorexia nervosa-II. *Journal of Clinical Endocrinology and Metabolism* **93** 1292–1297. (<https://doi.org/10.1210/jc.2007-2419>)
- Miyakoshi N, Richman C, Qin X, Baylink DJ & Mohan S 1999 Effects of recombinant insulin-like growth factor-binding protein-4 on bone formation parameters in mice. *Endocrinology* **140** 5719–5728. (<https://doi.org/10.1210/endo.140.12.7175>)
- Miyakoshi N, Kasukawa Y, Linkhart TA, Baylink DJ & Mohan S 2001a Evidence that anabolic effects of PTH on bone require IGF-I in growing mice. *Endocrinology* **142** 4349–4356. (<https://doi.org/10.1210/endo.142.10.8436>)
- Miyakoshi N, Richman C, Kasukawa Y, Linkhart TA, Baylink DJ & Mohan S 2001b Evidence that IGF-binding protein-5 functions as a growth factor. *Journal of Clinical Investigation* **107** 73–81. (<https://doi.org/10.1172/jci10459>)
- Mohan S, Thompson GR, Amaar YG, Hathaway G, Tschesche H & Baylink DJ 2002 ADAM-9 is an insulin-like growth factor binding protein-5 protease produced and secreted by human osteoblasts. *Biochemistry* **41** 15394–15403. (<https://doi.org/10.1021/bi026458q>)
- Mohan S, Richman C, Guo R, Amaar Y, Donahue LR, Wergedal J & Baylink DJ 2003 Insulin-like growth factor regulates peak bone mineral density in mice by both growth hormone-dependent and -independent mechanisms. *Endocrinology* **144** 929–936. (<https://doi.org/10.1210/en.2002-220948>)
- Müller EE, Locatelli V & Cocchi D 1999 Neuroendocrine control of growth hormone secretion. *Physiological Reviews* **79** 511–607.
- Muñoz-Torres M, Mezquita-Raya P, Lopez-Rodriguez F, Torres-Vela E, de Dios Luna J & Escobar-Jimenez F 2001 The contribution of IGF-I to skeletal integrity in postmenopausal women. *Clinical Endocrinology* **55** 759–766. (<https://doi.org/10.1046/j.1365-2265.2001.01390.x>)
- Nguyen TM, Arthur A, Paton S, Hemming S, Panagopoulos R, Codrington J, Walkley CR, Zannettino ACW & Gronthos S 2016 Loss of ephrinB1 in osteogenic progenitor cells impedes endochondral ossification and compromises bone strength integrity during skeletal development. *Bone* **93** 12–21. (<https://doi.org/10.1016/j.bone.2016.09.009>)
- Nordstrom SM, Tran JL, Sos BC, Wagner K-U & Weiss EJ 2011 Liver-derived IGF-I contributes to GH-dependent increases in lean mass and bone mineral density in mice with comparable levels of circulating GH. *Molecular Endocrinology* **25** 1223–1230. (<https://doi.org/10.1210/me.2011-0047>)
- Nunan R, Campbell J, Mori R, Pitulescu ME, Jiang WG, Harding KG, Adams RH, Nobes CD & Martin P 2015 Ephrin-Bs drive junctional downregulation and actin stress fiber disassembly to enable wound re-epithelialization. *Cell Reports* **13** 1380–1395. (<https://doi.org/10.1016/j.celrep.2015.09.085>)
- Ohlsson C, Mellström D, Carlzon D, Orwoll E, Ljunggren O, Karlsson MK & Vandenput L 2011 Older men with low serum IGF-1 have an increased risk of incident fractures: the MrOS Sweden study. *Journal of Bone and Mineral Research* **26** 865–872. (<https://doi.org/10.1002/jbmr.281>)
- O'Neill AK, Kindberg AA, Niethamer TK, Larson AR, Ho H-YH, Greenberg ME & Bush JO 2016 Unidirectional Eph/ephrin signaling creates a cortical actomyosin differential to drive cell segregation. *Journal of Cell Biology* **215** 217–229. (<https://doi.org/10.1083/jcb.201604097>)
- Paccou J, Dewailly J & Cortet B 2012 Reduced levels of serum IGF-1 is related to the presence of osteoporotic fractures in male idiopathic osteoporosis. *Joint, Bone, Spine: Revue Du Rhumatisme* **79** 78–82. (<https://doi.org/10.1016/j.jbspin.2011.06.002>)
- Qin X, Wergedal JE, Rehage M, Tran K, Newton J, Lam P, Baylink DJ & Mohan S 2006 Pregnancy-associated plasma protein-A increases osteoblast proliferation in vitro and bone formation in vivo. *Endocrinology* **147** 5653–5661. (<https://doi.org/10.1210/en.2006-1055>)
- Rajaram S, Baylink DJ & Mohan S 1997 Insulin-like growth factor-binding proteins in serum and other biological fluids: regulation and functions. *Endocrine Reviews* **18** 801–831. (<https://doi.org/10.1210/edrv.18.6.0321>)
- Reijnders CMA, Bravenboer N, Tromp AM, Blankenstein MA & Lips P 2007 Effect of mechanical loading on insulin-like growth factor-I gene expression in rat tibia. *Journal of Endocrinology* **192** 131–140. (<https://doi.org/10.1677/joe.1.06880>)
- Richman C, Baylink DJ, Lang K, Dony C & Mohan S 1999 Recombinant human insulin-like growth factor-binding protein-5 stimulates bone formation parameters in vitro and in vivo. *Endocrinology* **140** 4699–4705. (<https://doi.org/10.1210/endo.140.10.7081>)
- Risley M, Garrod D, Henkemeyer M & McLean W 2009 EphB2 and EphB3 forward signalling are required for palate development. *Mechanisms of Development* **126** 230–239. (<https://doi.org/10.1016/j.mod.2008.10.009>)
- Rosen CJ, Donahue LR & Hunter SJ 1994 Insulin-like growth factors and bone: the osteoporosis connection. *Proceedings of the Society for Experimental Biology and Medicine* **206** 83–102. (<https://doi.org/10.3181/00379727-206-43726>)
- Russell JD, Mira M, Allen BJ, Stewart PM, Vizzard J, Arthur B & Beumont PJ 1994 Protein repletion and treatment in anorexia nervosa. *American Journal of Clinical Nutrition* **59** 98–102. (<https://doi.org/10.1093/ajcn/59.1.98>)
- Sakata T, Halloran BP, Elalieh HZ, Munson SJ, Rudner L, Venton L, Ginzinger D, Rosen CJ & Bikle DD 2003 Skeletal unloading induces

- resistance to insulin-like growth factor I on bone formation. *Bone* **32** 669–680. ([https://doi.org/10.1016/S8756-3282\(03\)00088-7](https://doi.org/10.1016/S8756-3282(03)00088-7))
- Sakata T, Wang Y, Halloran BP, Elalieh HZ, Cao J & Bikle DD 2004 Skeletal unloading induces resistance to insulin-like growth factor-I (IGF-I) by inhibiting activation of the IGF-I signaling pathways. *Journal of Bone and Mineral Research* **19** 436–446. (<https://doi.org/10.1359/JBMR.0301241>)
- Sawada T, Jing X, Zhang Y, Shimada E, Yokote H, Miyajima M & Sakaguchi K 2010 Ternary complex formation of EphA4, FGFR and FRS2 α plays an important role in the proliferation of embryonic neural stem/progenitor cells. *Genes to Cells* **15** 297–311. (<https://doi.org/10.1111/j.1365-2443.2010.01391.x>)
- Sawada T, Arai D, Jing X, Miyajima M, Frank SJ & Sakaguchi K 2017 Molecular interactions of EphA4, growth hormone receptor, Janus kinase 2, and signal transducer and activator of transcription 5B. *PLoS ONE* **12** e0180785. (<https://doi.org/10.1371/journal.pone.0180785>)
- Scharla SH, Strong DD, Mohan S, Baylink DJ & Linkhart TA 1991 1,25-Dihydroxyvitamin D3 differentially regulates the production of insulin-like growth factor I (IGF-I) and IGF-binding protein-4 in mouse osteoblasts. *Endocrinology* **129** 3139–3146. (<https://doi.org/10.1210/endo-129-6-3139>)
- Schürch MA, Rizzoli R, Slosman D, Vadas L, Vergnaud P & Bonjour JP 1998 Protein supplements increase serum insulin-like growth factor-I levels and attenuate proximal femur bone loss in patients with recent hip fracture. A randomized, double-blind, placebo-controlled trial. *Annals of Internal Medicine* **128** 801–809. (<https://doi.org/10.7326/0003-4819-128-10-199805150-00002>)
- Seck T, Bretz A, Krempien R, Krempien B, Ziegler R & Pfeilschifter J 1999 Age-related changes in insulin-like growth factor I and II in human femoral cortical bone: lack of correlation with bone mass. *Bone* **24** 387–393. ([https://doi.org/10.1016/S8756-3282\(98\)00186-0](https://doi.org/10.1016/S8756-3282(98)00186-0))
- Shimizu E, Tamasi J & Partridge NC 2012 Alendronate affects osteoblast functions by crosstalk through EphrinB1-EphB. *Journal of Dental Research* **91** 268–274. (<https://doi.org/10.1177/0022034511432170>)
- Sjögren K, Liu JL, Blad K, Skrtic S, Vidal O, Wallenius V, LeRoith D, Törnell J, Isaksson OG, Jansson JO, et al. 1999 Liver-derived insulin-like growth factor I (IGF-I) is the principal source of IGF-I in blood but is not required for postnatal body growth in mice. *PNAS* **96** 7088–7092. (<https://doi.org/10.1073/pnas.96.12.7088>)
- Slootweg MC, Hoogerbrugge CM, de Poorter TL, Duursma SA & van Buul-Offers SC 1990 The presence of classical insulin-like growth factor (IGF) type-I and -II receptors on mouse osteoblasts: autocrine/paracrine growth effect of IGFs? *Journal of Endocrinology* **125** 271–277. (<https://doi.org/10.1677/joe.0.1250271>)
- Stadler HS, Higgins KM & Capecchi MR 2001 Loss of Eph-receptor expression correlates with loss of cell adhesion and chondrogenic capacity in Hoxa13 mutant limbs. *Development* **128** 4177–4188.
- Stiffel V, Amoui M, Sheng MH-C, Mohan S & Lau K-HW 2014 EphA4 receptor is a novel negative regulator of osteoclast activity. *Journal of Bone and Mineral Research* **29** 804–819. (<https://doi.org/10.1002/jbmr.2084>)
- Stratikopoulos E, Szabolcs M, Dragatsis I, Klinakis A & Efstratiadis A 2008 The hormonal action of IGF1 in postnatal mouse growth. *PNAS* **105** 19378–19383. (<https://doi.org/10.1073/pnas.0809223105>)
- Sunters A, Armstrong VJ, Zaman G, Kypta RM, Kawano Y, Lanyon LE & Price JS 2010 Mechano-transduction in osteoblastic cells involves strain-regulated estrogen receptor α -mediated control of insulin-like growth factor (IGF) I receptor sensitivity to Ambient IGF, leading to phosphatidylinositol 3-kinase/AKT-dependent Wnt/LRP5 receptor-independent activation of beta-catenin signaling. *Journal of Biological Chemistry* **285** 8743–8758. (<https://doi.org/10.1074/jbc.M109.027086>)
- Takyar FM, Tonna S, Ho PWM, Crimeen-Irwin B, Baker EK, Martin TJ & Sims NA 2013 EphrinB2/EphB4 inhibition in the osteoblast lineage modifies the anabolic response to parathyroid hormone. *Journal of Bone and Mineral Research* **28** 912–925. (<https://doi.org/10.1002/jbmr.1820>)
- Tanaka H & Liang CT 1996 Mitogenic activity but not phenotype expression of rat osteoprogenitor cells in response to IGF-I is impaired in aged rats. *Mechanisms of Ageing and Development* **92** 1–10. ([https://doi.org/10.1016/S0047-6374\(96\)01793-9](https://doi.org/10.1016/S0047-6374(96)01793-9))
- Tanner SJ, Hefferan TE, Rosen CJ & Conover CA 2008 Impact of pregnancy-associated plasma protein-a deletion on the adult murine skeleton. *Journal of Bone and Mineral Research* **23** 655–662. (<https://doi.org/10.1359/jbmr.071210>)
- Thissen J-P, Beauloye V, Ketelslegers J-M & Underwood LE 2004 Regulation of insulin-like growth factor-I by nutrition. In *IGF and Nutrition in Health and Disease*, pp 25–52. Eds MS Houston, JMP Holly & EL Feldman. Totowa, NJ: Humana Press. (https://doi.org/10.1007/978-1-59259-795-6_2)
- Tian F, Wang Y & Bikle DD 2018 IGF-1 signaling mediated cell-specific skeletal mechano-transduction. *Journal of Orthopaedic Research* **36** 576–583. (<https://doi.org/10.1002/jor.23767>)
- Ting M-C, Wu NL, Roybal PG, Sun J, Liu L, Yen Y & Maxson RE 2009 EphA4 as an effector of Twist1 in the guidance of osteogenic precursor cells during calvarial bone growth and in craniosynostosis. *Development* **136** 855–864. (<https://doi.org/10.1242/dev.028605>)
- Tonna S, Takyar FM, Vrahnas C, Crimeen-Irwin B, Ho PWM, Poulton JJ, Brennan HJ, McGregor NE, Allan EH, Nguyen H, et al. 2014 EphrinB2 signaling in osteoblasts promotes bone mineralization by preventing apoptosis. *FASEB Journal* **28** 4482–4496. (<https://doi.org/10.1096/fj.14-254300>)
- Tremolieres FA, Strong DD, Baylink DJ & Mohan S 1991 Insulin-like growth factor II and transforming growth factor beta 1 regulate insulin-like growth factor I secretion in mouse bone cells. *Acta Endocrinologica* **125** 538–546. (<https://doi.org/10.1530/acta.0.1250538>)
- van Varsseveld NC, Sohl E, Drent ML & Lips P 2015 Gender-specific associations of serum insulin-like growth factor-1 with bone health and fractures in older persons. *Journal of Clinical Endocrinology and Metabolism* **100** 4272–4281. (<https://doi.org/10.1210/jc.2015-2549>)
- Veldhuis JD, Frystyk J, Iranmanesh A & Ørskov H 2005 Testosterone and estradiol regulate free insulin-like growth factor I (IGF-I), IGF binding protein 1 (IGFBP-1), and dimeric IGF-I/IGFBP-1 concentrations. *Journal of Clinical Endocrinology and Metabolism* **90** 2941–2947. (<https://doi.org/10.1210/jc.2004-1314>)
- Wang Y, Cheng Z, Elalieh HZ, Nakamura E, Nguyen M-T, Mackem S, Clemens TL, Bikle DD & Chang W 2011 IGF-1R signaling in chondrocytes modulates growth plate development by interacting with the PTHrP/Ihh pathway. *Journal of Bone and Mineral Research* **26** 1437–1446. (<https://doi.org/10.1002/jbmr.359>)
- Wang M, Liu C, Zhang Y, Hao Y, Zhang X & Zhang YM 2013 Protein interaction and microRNA network analysis in osteoarthritis meniscal cells. *Genetics and Molecular Research* **12** 738–746. (<https://doi.org/10.4238/2013.March.13.2>)
- Wang Y, Menendez A, Fong C, ElAlieh HZ, Chang W & Bikle DD 2014 Ephrin B2/EphB4 mediates the actions of IGF-I signaling in regulating endochondral bone formation. *Journal of Bone and Mineral Research* **29** 1900–1913. (<https://doi.org/10.1002/jbmr.2196>)
- Wang Y, Menendez A, Fong C, ElAlieh HZ, Kubota T, Long R & Bikle DD 2015 IGF-I signaling in osterix-expressing cells regulates secondary ossification center formation, growth plate maturation, and metaphyseal formation during postnatal bone development. *Journal of Bone and Mineral Research*. (<https://doi.org/10.1002/jbmr.2563>)
- Wang C, Shan S, Wang C, Wang J, Li J, Hu G, Dai K, Li Q & Zhang X 2017 Mechanical stimulation promote the osteogenic differentiation of bone marrow stromal cells through epigenetic regulation of Sonic Hedgehog. *Experimental Cell Research* **352** 346–356. (<https://doi.org/10.1016/j.yexcr.2017.02.021>)
- Warren MP, Brooks-Gunn J, Fox RP, Holderness CC, Hyle EP & Hamilton WG 2002 Osteopenia in exercise-associated amenorrhea using ballet dancers as a model: a longitudinal study. *Journal of*

- Clinical Endocrinology and Metabolism* **87** 3162–3168. (<https://doi.org/10.1210/jcem.87.7.8637>)
- Wilkinson DG 2014 Regulation of cell differentiation by Eph receptor and ephrin signaling. *Cell Adhesion and Migration* **8** 339–348. (<https://doi.org/10.4161/19336918.2014.970007>)
- Xing W, Baylink D, Kesavan C, Hu Y, Kapoor S, Chadwick RB & Mohan S 2005 Global gene expression analysis in the bones reveals involvement of several novel genes and pathways in mediating an anabolic response of mechanical loading in mice. *Journal of Cellular Biochemistry* **96** 1049–1060. (<https://doi.org/10.1002/jcb.20606>)
- Xing W, Kim J, Wergedal J, Chen S-T & Mohan S 2010 Ephrin B1 regulates bone marrow stromal cell differentiation and bone formation by influencing TAZ transactivation via complex formation with NHERF1. *Molecular and Cellular Biology* **30** 711–721. (<https://doi.org/10.1128/MCB.00610-09>)
- Xing W, Govoni KE, Donahue LR, Kesavan C, Wergedal J, Long C, Bassett JHD, Gogakos A, Wojcicka A, Williams GR, *et al.* 2012 Genetic evidence that thyroid hormone is indispensable for prepubertal insulin-like growth factor-I expression and bone acquisition in mice. *Journal of Bone and Mineral Research* **27** 1067–1079. (<https://doi.org/10.1002/jbmr.1551>)
- Yakar S, Liu JL, Stannard B, Butler A, Accili D, Sauer B & LeRoith D 1999 Normal growth and development in the absence of hepatic insulin-like growth factor I. *PNAS* **96** 7324–7329. (<https://doi.org/10.1073/pnas.96.13.7324>)
- Yakar S, Rosen CJ, Beamer WG, Ackert-Bicknell CL, Wu Y, Liu J-L, Ooi GT, Setser J, Frystyk J, Boisclair YR, *et al.* 2002 Circulating levels of IGF-1 directly regulate bone growth and density. *Journal of Clinical Investigation* **110** 771–781. (<https://doi.org/10.1172/JCI15463>)
- Yakar S, Rosen CJ, Bouxsein ML, Sun H, Mejia W, Kawashima Y, Wu Y, Emerton K, Williams V, Jepsen K, *et al.* 2009 Serum complexes of insulin-like growth factor-1 modulate skeletal integrity and carbohydrate metabolism. *FASEB Journal* **23** 709–719. (<https://doi.org/10.1096/fj.08-118976>)
- Yamada T, Yuasa M, Masaoka T, Taniyama T, Maehara H, Torigoe I, Yoshii T, Shinomiya K, Okawa A & Sotome S 2013 After repeated division, bone marrow stromal cells express inhibitory factors with osteogenic capabilities, and EphA5 is a primary candidate. *Bone* **57** 343–354. (<https://doi.org/10.1016/j.bone.2013.08.028>)
- Yamada T, Yoshii T, Yasuda H, Okawa A & Sotome S 2016 Dexamethasone regulates EphA5, a potential inhibitory factor with osteogenic capability of human bone marrow stromal cells. *Stem Cells International* **2016** 1301608. (<https://doi.org/10.1155/2016/1301608>)
- Yamaguchi M, Ogata N, Shinoda Y, Akune T, Kamekura S, Terauchi Y, Kadowaki T, Hoshi K, Chung U-I, Nakamura K, *et al.* 2005 Insulin receptor substrate-1 is required for bone anabolic function of parathyroid hormone in mice. *Endocrinology* **146** 2620–2628. (<https://doi.org/10.1210/en.2004-1511>)
- Zhang J & Hughes S 2006 Role of the ephrin and Eph receptor tyrosine kinase families in angiogenesis and development of the cardiovascular system. *Journal of Pathology* **208** 453–461. (<https://doi.org/10.1002/path.1937>)
- Zhang X, Sobue T & Hurley MM 2002a FGF-2 increases colony formation, PTH receptor, and IGF-1 mRNA in mouse marrow stromal cells. *Biochemical and Biophysical Research Communications* **290** 526–531. (<https://doi.org/10.1006/bbrc.2001.6217>)
- Zhang M, Xuan S, Bouxsein ML, von Stechow D, Akeno N, Faugere MC, Malluche H, Zhao G, Rosen CJ, Efstratiadis A, *et al.* 2002b Osteoblast-specific knockout of the insulin-like growth factor (IGF) receptor gene reveals an essential role of IGF signaling in bone matrix mineralization. *Journal of Biological Chemistry* **277** 44005–44012. (<https://doi.org/10.1074/jbc.M208265200>)
- Zhao G, Monier-Faugere MC, Langub MC, Geng Z, Nakayama T, Pike JW, Chernausk SD, Rosen CJ, Donahue LR, Malluche HH, *et al.* 2000 Targeted overexpression of insulin-like growth factor I to osteoblasts of transgenic mice: increased trabecular bone volume without increased osteoblast proliferation. *Endocrinology* **141** 2674–2682. (<https://doi.org/10.1210/endo.141.7.7585>)
- Zhao C, Irie N, Takada Y, Shimoda K, Miyamoto T, Nishiwaki T, Suda T & Matsuo K 2006 Bidirectional ephrinB2-EphB4 signaling controls bone homeostasis. *Cell Metabolism* **4** 111–121. (<https://doi.org/10.1016/j.cmet.2006.05.012>)
- Zofková I, Bahbouh R & Bendlová B 2001 Systemic insulin-like growth factor-I, insulin and vitamin D status in relation to age-associated bone loss in women. *Experimental and Clinical Endocrinology and Diabetes* **109** 267–272. (<https://doi.org/10.1055/s-2001-16346>)

Received in final form 26 February 2018

Accepted 26 March 2018

Accepted Preprint published online 26 March 2018